Oxford BioMedica plc · LSE:OXB
Oxford BioMedica — FY2015 Earnings Presentation
20 slides from Oxford BioMedica's earnings presentation, Apr 28, 2016
Slide 1: Oxford BioMedica 2015 preliminary results
Q Oxford
Slide 2: Forward-looking statements
Forward-looking statements This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair
Slide 3: Operational highlights including post period-end (1/2)
Operational highlights including post period-end (1/2) • Strong progress from LentiVector® delivery platform Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) • Portfolio review in Q1 2016: focus on OXB-102, 1, n =3 1x Original Mean 27% Mean 30% Mean 29%
Slide 4: Operational highlights including post period-end (2/2)
Operational highlights including post period-end (2/2) • Investment in people, facilities and plant • Headcount increased from 134 to 231 Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) • New Yarnton 1, n =3 1x facility operational Original Mean 27% Mean
Slide 5: Financial highlights
Financial highlights • 28%(1) growth in gross income(2) • 72% growth in income from process Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, development and bioprocessing n =3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50%
Slide 6: Strategic review
Slide 7: Strategic review confirms Oxford BioMedica as leader in field
Strategic review confirms Oxford BioMedica as leader in field • Gene and cell therapy field set to grow into $ multi-billion sector over next 5-10 years. Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) Several products, particularly ex vivo, likely 1, n
Slide 8: In depth conclusions from strategic review
In depth conclusions from strategic review • Successful companies will be those which own or have economic interests in gene and cell therapy products Cohort2 • Oxford BioMedica Dose is and will Administration remain a product-focused company: we now focus on 3 months (UPDRS) 6 months (UPDRS) 1 yea
Slide 9: Products
Products Slide for large image Oxford BioMedica has an interest in many gene and cell therapy projects and our integrated platform technology is instrumental in the following wholly-owned and partnered / royalty-bearing programmes Research/ Product Indication Phase I Phase I/II Phase II Phase III
Slide 10: OXB-102 for Parkinson's disease
OXB-102 for Parkinson’s disease Overview Programme Status OXB-101 (ProSavin®)/OXB-102 aims to provide • Phase I/II regulatory approval submission underway dopamine (DA) replacement Cohort2 Dose to patients with Administration 3 months (UPDRS) • Study protocol 6 months (UPDRS) filed with MHRA (UK
Slide 11: OXB-202 for Corneal Graft Rejection
OXB-202 for Corneal Graft Rejection Overview Illustrative Results OXB-202 is designed to prevent corneal graft rejection Efficacy in rabbit model of Reduction in corneal NV, rejection (aggressive) 3 opacity and immune • 2Despite one oDose Cohort f the most successful tissue transplants, Administra
Slide 12: OXB-302 for targeting solid cancer tumours (CAR-T 5T4)
OXB-302 for targeting solid cancer tumours (CAR-T 5T4) Overview Illustrative Results • Chimeric Antigen Receptors (CARs) enable the re- Expression of 5T4 on primary and metastatic direction Cohort2 o f a patient’s Dose T cells t o target cancer Administration c ells human 6 months 3 months (UPDRS
Slide 13: LentiVector platform evidence of long-term duration
LentiVector® platform evidence of long-term duration • Improvement in motor function sustained in most patients for up to 3 years (OXB-101) Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) • 4 year follow up data available soon 1, n =3 1x Original Mean 2
Slide 14: Financial review
Financial review
Slide 15: Financial review (1)
Financial review (1) Operating loss 2015 2014 Comments £m £m Gross income (2) 18.8 14.7 +28% including a 72% increase in process development and Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) bioprocessing fees (£12.4m in 2015) 1, n =3 1x Original Mean 2
Slide 16: Financial outlook
Financial outlook • Bioprocessing and process development revenues set to continue strong growth as new capacity comes on stream Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n =3 1x Original Mean st27% Mean 30% st29% Mean Mean 20% £m 1 3 months Max.
Slide 17: Conclusions
Slide 18: 2016 potential newsflow
2016 potential newsflow • In-house priority products • OXB-102 Phase I/II first patient dosed Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n =3 • OXB-202 Phase I/II 1x study CTA filing Original Mean 2i n H2 7% Mean 30% Mean 29% Mean 20% Max. up t
Slide 19: Conclusions
Conclusions • Significantly upgraded capacity/capabilities of LentiVector® delivery platform Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n =3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% • Attracting interest from many developers of lentiviral v
Slide 20: Thank you
Thank you